Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Objective: Exposure to supraphysiologic levels of glucocorticoid drugs is known to have detrimental effects on bone formation and linear growth. Patients with sclerosteosis lack the bone regulatory protein sclerostin, have excessive bone formation, and are typically above average in height. This study was undertaken to characterize the effects of a monoclonal antibody to sclerostin (Scl‐AbI) in mice exposed to dexamethasone (DEX). Methods: Young mice were concomitantly treated with DEX (or vehicle control) and Scl‐AbI antibody (or isotype‐matched control antibody [Ctrl‐Ab]) in 2 independent studies. Linear growth, the volume and strength of the bones, and the levels of bone turnover markers were analyzed. Results: In DEX‐treated mice, Scl‐AbI had no significant effect on linear growth when compared to control treatment (Ctrl‐Ab). However, in mice treated with DEX and Scl‐ABI, a significant increase in trabecular bone at the femoral metaphysis (bone volume/total volume +117% versus Ctrl‐Ab–treated mice) and in the width and volume of the cortical bone at the femoral diaphysis (+24% and +20%, respectively, versus Ctrl‐Ab–treated mice) was noted. Scl‐AbI treatment also improved mechanical strength (as assessed by 4‐point bending studies) at the femoral diaphysis in DEX‐treated mice (maximum load +60% and ultimate strength +47% in Scl‐AbI–treated mice versus Ctrl‐Ab–treated mice). Elevated osteocalcin levels were not detected in DEX‐treated mice that received Scl‐AbI, although levels of type 5b tartrate‐resistant acid phosphatase were significantly lower than those observed in mice receiving DEX and Ctrl‐Ab. Conclusion: Scl‐AbI treatment does not prevent the detrimental effects of DEX on linear growth, but the antibody does increase both cortical and trabecular bone and improves bone mechanical properties in DEX‐treated mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Basic biomechanical measurements of bone: A tutorial
Turner, C. H., & Burr, D. B. (1993) · Bone · doi:10.1016/8756-3282(93)90081-k · Cited by 1,666
Regulation of bone mass by Wnt signaling
Krishnan, V. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28551 · Cited by 1,407
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
Population‐based assessment of adverse events associated with long‐term glucocorticoid use
Curtis, J. R., Westfall, A. O., Allison, J., Bijlsma, J. W., Freeman, A., George, V., Kovac, S. H., Spettell, C. M., & Saag, K. G. (2006) · Arthritis Care & Research · doi:10.1002/art.21984 · Cited by 595
Lane, N. E., Yao, W., Balooch, M., Nalla, R. K., Balooch, G., Habelitz, S., Kinney, J. H., & Bonewald, L. F. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051103 · Cited by 355
Molecular mechanisms of glucocorticoid-induced osteoporosis.
Patschan, D., Loddenkemper, K., & Buttgereit, F. (2001) · Bone · doi:10.1016/s8756-3282(01)00610-x · Cited by 201
Yao, W., Cheng, Z., Pham, A., Busse, C., Zimmermann, E. A., Ritchie, R. O., & Lane, N. E. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23954 · Cited by 128
Cited by
The Osteocyte: An Endocrine Cell … and More
Dallas, S. L., Prideaux, M., & Bonewald, L. F. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1026 · Cited by 1,042
Role and mechanism of action of sclerostin in bone
Delgado-Calle, J., Sato, A. Y., & Bellido, T. (2017) · Bone · doi:10.1016/j.bone.2016.10.007 · Cited by 443
Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases
Ke, H. Z., Richards, W. G., Li, X., & Ominsky, M. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1060 · Cited by 402
Pathogenic mechanisms of glucocorticoid-induced osteoporosis
Chen, M., Fu, W., Xu, H., & Liu, C.-J. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.03.002 · Cited by 146
Romosozumab for the treatment of osteoporosis
Bandeira, L., Lewiecki, E. M., & Bilezikian, J. P. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1280455 · Cited by 101
Metadata
- Authors
- Marenzana, M., Greenslade, K., Eddleston, A., Okoye, R., Marshall, D., Moore, A., & Robinson, M. K.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2011-08
- Volume
- 63
- Issue
- 8
- Pages
- 2385-2395
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2057472181
- Cited by
- 73
- References
- 8
- FWCI
- 8.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.